An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma

Keyphrases

• Multiple Myeloma 100%
• Plateau Phase 100%
• Phase II Trial 100%
• Denosumab 100%
• Myeloma 50%
• Stable Disease 33%
• Myeloma Cells 33%
• Disease Progression 16%
• Protein Level 16%
• Controlled Experiment 16%
• Bone Marrow 16%
• Dosing Schedule 16%
• Nineteen 16%
• Preclinical Data 16%
• Complete Response 16%
• Partial Response 16%
• Systemic Therapy 16%
• Osteoclast 16%
• Tumor Burden 16%
• Bisphosphonates 16%
• M Protein 16%
• Response Criteria 16%
• Objective Response 16%
• Bone Turnover Markers 16%
• Receptor Activator of nuclear factor-κB Ligand (RANKL) 16%
• Osteoclast Differentiation 16%
• Osteoclast Activation 16%
• RANKL Inhibitors 16%
• Paraprotein 16%
• Therapeutic Role 16%
• Single-arm Study 16%
• Osteoclast Survival 16%
• Past Exposure 16%
• C-terminal Telopeptide of Type I Collagen 16%
• Loading Dose 16%
• Advanced Cancer Patients 16%
• Adverse Events Profile 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Multiple Myeloma 100%
• Denosumab 100%
• Osteoclast Differentiation Factor 83%
• Myeloma 66%
• Diseases 50%
• Neoplasm 16%
• Adverse Event 16%
• Clinical Study 16%
• Disease Exacerbation 16%
• Bisphosphonic Acid Derivative 16%
• M Protein 16%
• Advanced Cancer 16%
• Collagen Type 1 16%
• Paraprotein 16%
• Telopeptide 16%

Immunology and Microbiology

• Multiple Myeloma 100%
• Denosumab 100%
• RANKL 83%
• Myeloma Cell 33%
• Mediator 16%
• Carboxy Terminal Sequence 16%
• Osteoclast 16%
• Arm 16%
• Osteoclastogenesis 16%
• Tumor Volume 16%
• RANK 16%
• Myeloma Protein 16%
• Loading Drug Dose 16%
• Bone Turnover 16%